Back to Search
Start Over
No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.
- Source :
-
The Canadian journal of cardiology [Can J Cardiol] 2013 May; Vol. 29 (5), pp. 586-91. Date of Electronic Publication: 2013 Mar 29. - Publication Year :
- 2013
-
Abstract
- Background: Some evidence suggests that the direct renin inhibitor aliskiren may increase the risk of severe hyperkalemia, stroke, or acute kidney injury (AKI) when prescribed with angiotensin-converting enzyme inhibitors (ACEi's) or angiotensin-receptor blockers (ARBs). The extent to which concomitant treatment increases the risk of these outcomes in routine clinical practice is unknown. We addressed this issue with the use of administrative databases.<br />Methods: We established a cohort of Ontarians treated with an ACEi or an ARB. Within this cohort, we conducted 3 case-control studies. Cases were patients hospitalized with 1 of 3 outcomes (hyperkalemia, AKI, or stroke). In each analysis, we identified up to 5 matched control subjects for each case. Conditional logistic regression was used to examine the association between hospitalization for each outcome and the use of aliskiren in the preceding 60 days.<br />Results: Among 903,346 patients aged 66 years and older treated with an ACEi or ARB during the 28-month study period, we identified 4235 hospitalized with hyperkalemia, 18,231 hospitalized with AKI, and 8283 hospitalized with stroke. After extensive multivariable adjustment, aliskiren therapy was not associated with a significant increase in the risk of hospitalization for hyperkalemia, AKI, or stroke. We found similar results in stratified analyses of patients with and without a history of chronic kidney disease, diabetes, or heart failure.<br />Conclusions: Among community-dwelling patients aged 66 years and older receiving therapy with an ACEi or an ARB, aliskiren use was not associated with hospitalization for hyperkalemia, AKI, or stroke.<br /> (Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Acute Kidney Injury epidemiology
Aged
Aged, 80 and over
Amides therapeutic use
Case-Control Studies
Cohort Studies
Drug Therapy, Combination
Female
Fumarates therapeutic use
Hospitalization
Humans
Hyperkalemia epidemiology
Logistic Models
Male
Ontario epidemiology
Renin adverse effects
Renin antagonists & inhibitors
Renin therapeutic use
Risk Factors
Stroke epidemiology
Acute Kidney Injury chemically induced
Amides adverse effects
Angiotensin Receptor Antagonists therapeutic use
Angiotensin-Converting Enzyme Inhibitors therapeutic use
Fumarates adverse effects
Hyperkalemia chemically induced
Stroke chemically induced
Subjects
Details
- Language :
- English
- ISSN :
- 1916-7075
- Volume :
- 29
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- The Canadian journal of cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 23541666
- Full Text :
- https://doi.org/10.1016/j.cjca.2013.02.015